Results 21 to 30 of about 5,453 (193)

In Vitro Activity of 22 Antibiotics against Achromobacter Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options?

Microorganisms, 2021
Bacteria belonging to the genus Achromobacter are increasingly isolated from respiratory samples of people with cystic fibrosis (PWCF). The management of this multidrug-resistant genus is challenging and characterised by a lack of international ...
Clémence Beauruelle, Claudie Lamoureux, Arsid Mashi, Sophie Ramel, Jean Le Bihan, Thomas Ropars, Anne Dirou, Anandadev Banerjee, Didier Tandé, Hervé Le Bars, Geneviève Héry-Arnaud   +10 more
doaj   +1 more source

Efficacy of Ruxolitinib in Severe Pediatric Intra-Alveolar Hemorrhages Unrelated to COPA Mutations. [PDF]

Pediatr Pulmonol
Pediatric Pulmonology, Volume 60, Issue 1, January 2025.
Le A, Perrin T, Drummond D, Reix P, Bader-Meunier B, Rice GI, Duffy D, Frémond ML, Hadchouel A.   +8 more
europepmc   +2 more sources

Prospective Evaluation of Cardiorespiratory Fitness After Hematopoietic Stem Cell Transplantation in Children. [PDF]

Pediatr Pulmonol
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with long‐term sequelae such as reduced exercise capacity, but whether some degree of spontaneous recovery occurs during childhood is yet to be determined. This prospective multicenter study aimed to evaluate exercise capacity at 1 and 3 years after HSCT.
Houdouin V, Feghali H, Boileau S, Guinot M, Reix P, Pages J, Crepon SG, Delclaux C.   +7 more
europepmc   +2 more sources

Correction to: In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study

BMC Medicine, 2018
The original article [1] contains errors in Table 1 affecting some of the presented oligonucleotide sequences and readthrough values in Table 1.
I. Sermet-Gaudelus, M. Renouil, A. Fajac, L. Bidou, B. Parbaille, S. Pierrot, N. Davy, E. Bismuth, P. Reinert, G. Lenoir, J. F. Lesure, J. P. Rousset, A. Edelman   +12 more
doaj   +1 more source

Improved lung function using a therapeutic educational multidisciplinary program in a pediatric cystic fibrosis clinic [PDF]

, 2013
Background: Pulmonary disease remains the most common cause of morbidity and mortality in cystic fibrosis. The clearing of mucus by chest physiotherapy is a major keystone of treatment.
Ballabeni, Pierluigi, Durussel, Claudine, Hafen, Gaudenz Martin, Kernen, Yann   +3 more
core   +1 more source

AVALIAÇÃO POSTURAL COMPUTADORIZADA EM PACIENTES PORTADORES DA FIBROSE CÍSTICA EM UM CENTRO DE REFERÊNCIA EM SALVADOR-BA

Revista Pesquisa em Fisioterapia, 2015
Introdução: A Fibrose Cística (FC) é uma anormalidade genética de caráter sistêmico gerando ao sistema respiratório uma hipersecretividade e obstrução brônquica crônica.
Francisco Oliveira, Cristiane Dias, Anna Lúcia Dinniz, Selena Márcia Dubois Mendes, Abrahão Fontes Baptista, Kátia Nunes Sá   +5 more
doaj   +1 more source

Diagnostic prénatal et diagnostic pré-implantatoire : arbre décisionnel, nouvelles pratiques ? [PDF]

, 2005
Le diagnostic pré-implantatoire (DPI) a pour objectif l’étude des caractéristiques génétiques d’un embryon âgé de trois jours. Il offre ainsi à des couples ayant un risque élevé de transmettre une maladie héréditaire une alternative au diagnostic ...
Feyereisen, Estelle, Frydman, Nelly, Kerbrat, Violaine, Romana, Serge, Steffann, Julie   +4 more
core   +1 more source

Early chest CT abnormalities to predict the subsequent occurrence of chronic lung allograft dysfunction

Insights into Imaging, 2023
Introduction Chronic lung allograft dysfunction (CLAD) can take two forms: bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndrome (RAS).
Paul Habert, Elsa Chetrit, Benjamin Coiffard, Fabienne Bregeon, Pascal Thomas, Anderson Loundou, Julien Bermudez, Martine Reynaud-Gaubert, Jean-Yves Gaubert   +8 more
doaj   +1 more source

Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators

Cells, 2021
Cystic fibrosis is a severe autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene encoding the CFTR protein, a chloride channel expressed in many epithelial cells.
Isabelle Fajac, Isabelle Sermet
doaj   +1 more source

Quality of care in cystic fibrosis: assessment protocol of the French QIP PHARE-M

Orphanet Journal of Rare Diseases, 2018
Background The PHARE-M care quality improvement program, modeled on the US Cystic Fibrosis Quality Improvement Program, was introduced at 14 cystic fibrosis centers (CFCs) in the French Cystic Fibrosis Network between 2011 and 2013.
Dominique Pougheon Bertrand, Emmanuel Nowak, Clémence Dehillotte, Lydie Lemmonier, Gilles Rault   +4 more
doaj   +1 more source